Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis

References

• Hamada S, Gulliford MC. Antidiabetic and cardiovascular drug utilisation in patients diagnosed with type 2 diabetes mellitus over the age of 80 years: a population-based cohort study. Age Ageing. 2015;44:566–573.
   PubMed Web of Science ®Google Scholar
• Meneilly GS. Diabetes in the elderly. Med Clin North Am. 2006;90:909–923.
   PubMed Web of Science ®Google Scholar
• Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511–530.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Personalising metformin therapy: a clinician’s perspective. Lancet Diabetes Endocrinol. 2014;2:442–444.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: Centers for Disease Control and Prevention; 2011.
   Google Scholar
• Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care. 2006;29:2415–2419.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–559.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Miller ME, Williamson JD, Gerstein HC, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care. 2014;37:634–643.
   PubMed Web of Science ®Google Scholar
• Bode BW, Brett J, Falahati A, et al. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother. 2011;9:423–433.
   PubMedGoogle Scholar
• Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31:203–214.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Takai M, Maeda H, et al. Predicting therapeutic efficacy of combination treatment with sitagliptin and insulin in type 2 diabetic patients: the ASSIST-K study. J Clin Med Res. 2015;7:607–612.
   PubMedGoogle Scholar
• Lankisch MR, Del Prato S, Dain MP, et al. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: a pooled analysis of four clinical trials. Prim Care Diabetes. 2015. pii: S1751-9918, 00073-X. doi:10.1016/j.pcd.2015.05.003.
   PubMed Web of Science ®Google Scholar
• Yagi S, Aihara K, Sata M, et al. Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. Diabetes Metab J. 2015;39:342–347.
   PubMed Web of Science ®Google Scholar
• Umezawa S, Kubota A, Maeda H, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord. 2015;15:34.
   PubMed Web of Science ®Google Scholar
• Lapolla A, Frison V, Bettio M, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther. 2015;37:574–584.
   PubMed Web of Science ®Google Scholar
• Amutha A, Ali MK, Unnikrishnan R, et al. Insulin sensitivity and secretion in youth onset type 2 diabetes with and without visceral adiposity. Diabetes Res Clin Pract. 2015;109:32–39.
   PubMed Web of Science ®Google Scholar
• Bruun C, Siersma V, Guassora AD, et al. Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. the role of age, gender and co-morbidity. Diabet Med. 2013;30:964–972.
   PubMed Web of Science ®Google Scholar
• Monteiro-Soares M, Boyko E, Ribeiro J, et al. Predictive factors for diabetic foot ulceration: a systematic review. Diabetes Metab Res Rev. 2012;28:574–600.
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126–133.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Toyoda M, Yokoyama H, Abe K, et al. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106:451–457.
   PubMed Web of Science ®Google Scholar
• Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract. 2005;67:43–52.
   PubMed Web of Science ®Google Scholar
• Charpentier G, Vaur L, Halimi S, et al. Predictors of response to glimepiride in patients with type 2 diabetes mellitus. Diabetes Metab. 2001;27:563–571.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
   PubMed Web of Science ®Google Scholar
• Kim SA, Shim WH, Lee EH, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159–165.
   PubMedGoogle Scholar
• Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27:362–372.
   PubMed Web of Science ®Google Scholar